Table 2.
Baseline Demography of the Patient Population
|
Median age, years [range] |
61 [29–87] |
|---|---|
| No. of patients (%) | |
|
Sex |
|
| Female |
27 (14) |
| Male |
171 (86) |
|
Primary tumor site |
|
| Oral cavity |
54 (27) |
| Oropharynx |
55 (28) |
| Hypopharynx |
47 (24) |
| Larynx |
21 (11) |
| Other* |
21 (11) |
|
Tumor stage at initial diagnosis |
|
| I |
11 (6) |
| II |
21 (11) |
| III |
23 (12) |
| IVa |
106 (54) |
| IVb |
16 (8) |
| IVc |
13 (7) |
| Unknown |
8 (4) |
|
Initial treatment |
|
| Neoadjuvant platinum based chemotherapy |
52 (26) |
| With Fluorouracil |
43 (22) |
| With Taxanes |
41 (21) |
| Surgery |
142 (72) |
| Radiotherapy |
168 (85) |
| Alone |
73 (37) |
| With platinum |
74 (37) |
| With cetuximab |
20 (10) |
| With taxanes |
1 (1) |
|
Pattern of disease |
|
| Primary metastatic |
13 (7) |
| Primary locally advanced (palliative treatment) |
8 (4) |
| Relapse |
177 (89) |
| Local only |
126 (63) |
| Metastatic +/- local |
51 (26) |
|
Eligibility for inclusion in a clinical trial | |
| Yes |
131 (66) |
| No |
67 (34) |
| PS ≥ 2 |
53 (27) |
| Relapse after initial therapy ≤ 6 months |
27 (14) |
| Other concomitant malignancy |
3 (2) |
| Major comorbidity |
3 (2) |
|
PS at onset of palliative chemotherapy | |
| 0 |
28 (14) |
| 1 |
117 (59) |
| ≥ 2 | 53 (27) |
*Four nasopharynx, 12 sinus tumor, 5 primitive adenopathies.
PS = Perormans Status.